Avalanche Biotechnologies Inc (AAVL)

3.33
0.09 2.78
NASDAQ : Health Care
Prev Close 3.24
Open 3.28
Day Low/High 3.24 / 3.41
52 Wk Low/High 2.99 / 15.63
Volume 227.32K
Avg Volume 327.50K
Exchange NASDAQ
Shares Outstanding 27.13M
Market Cap 112.32M
EPS -1.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These under-$10 stock look poised to break out and trade higher from current levels.

The Bears Come Out of the Woods

It doesn't take much to get them chattering.

Avalanche Shareholders Push Back Against Gene Therapy Reboot Merger

Avalanche Shareholders Push Back Against Gene Therapy Reboot Merger

Some Avalanche shareholders prefer liquidation of the company instead of the proposed merger with Annapurna Therapeutics.

Avalanche Biotechnologies And Annapurna Therapeutics Announce Proposed Merger

Avalanche Biotechnologies And Annapurna Therapeutics Announce Proposed Merger

Combined Scientific, Financial and Human Resources Will Support Robust Gene Therapy Pipeline Companies to Host Conference Call Today at 8:00 a.m. ET/ 5:00 a.m. PT

Avalanche Biotechnologies Becomes Oversold (AAVL)

Avalanche Biotechnologies Becomes Oversold (AAVL)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

3 Biotech Stocks Under $10 Making Big Moves

3 Biotech Stocks Under $10 Making Big Moves

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

5 Stocks Under $10 Setting Up to Trade Higher

5 Stocks Under $10 Setting Up to Trade Higher

Here's how to trade five low-priced stocks poised to move higher.

5 Biotech Stocks Under $10 Triggering Breakout Trades

5 Biotech Stocks Under $10 Triggering Breakout Trades

Keep these under-$10 biotech stocks on your breakout trading radar.

Avalanche Biotechnologies is Now Oversold (AAVL)

Avalanche Biotechnologies is Now Oversold (AAVL)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Spark Therapeutics Trial Success Seen As Positive For Gene Therapy Sector

Spark Therapeutics Trial Success Seen As Positive For Gene Therapy Sector

The shares of Spark Therapeutics are surging after the company announced that its lead gene therapy product candidate had met its primary endpoint in a Phase 3 trial.

Spark Tries to Quell Investor Fears About Gene Therapy Test

Spark Tries to Quell Investor Fears About Gene Therapy Test

Spark Therapeutics provided details Thursday about changes made to a clinical trial involving the company's gene therapy, trying to calm jittery biotech investors before study results next month.

IMPORTANT SHAREHOLDER NOTICE: Khang & Khang LLP Announces The Filing Of A Securities Class Action Lawsuit Against Avalanche Biotechnologies, Inc. And Encourages Investors To Contact The Firm

IMPORTANT SHAREHOLDER NOTICE: Khang & Khang LLP Announces The Filing Of A Securities Class Action Lawsuit Against Avalanche Biotechnologies, Inc. And Encourages Investors To Contact The Firm

Khang & Khang LLP (the "Firm") announces that a class action lawsuit has been filed against Avalanche Biotechnologies, Inc.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ATLC, CBFV, COT, DYAX, FRPH, JMP, MAS, MTRX Downgrades: ANIP, COHR, CORR, CXP, DCT, DOM, EDE, FE, HGR, HMG, MBVT, QCRH, QLYS Initiations: AAVL, CTLT, RIGP, SPKE, SYF, WLKP Read on to get TheStreet Quant Ratings' detailed report:

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Avalanche Biotechnologies, Inc. Of Pendency Of Class Action Lawsuit And A Lead Plaintiff Deadline Of September 8, 2015

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Avalanche Biotechnologies, Inc. Of Pendency Of Class Action Lawsuit And A Lead Plaintiff Deadline Of September 8, 2015

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Avalanche Biotechnologies, Inc.

Relative Strength Alert For Avalanche Biotechnologies

Relative Strength Alert For Avalanche Biotechnologies

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

TRADING ALERT: The Rosen Law Firm Reminds Avalanche Biotechnologies, Inc. Investors Of The Important Deadline In The Class Action Lawsuit Filed By The Firm - AAVL

TRADING ALERT: The Rosen Law Firm Reminds Avalanche Biotechnologies, Inc. Investors Of The Important Deadline In The Class Action Lawsuit Filed By The Firm - AAVL

The Rosen Law Firm, a global investor rights law firm, reminds purchasers of Avalanche Biotechnologies, Inc.

Commit To Buy Avalanche Biotechnologies At $12.50, Earn 19.8% Annualized Using Options

Commit To Buy Avalanche Biotechnologies At $12.50, Earn 19.8% Annualized Using Options

Investors considering a purchase of Avalanche Biotechnologies, Inc. stock, but tentative about paying the going market price of $16.70/share, might benefit from considering selling puts among the alternative strategies at their disposal.

EQUITY ALERT: The Rosen Law Firm Files Securities Class Action Lawsuit Against Avalanche Biotechnologies, Inc.

EQUITY ALERT: The Rosen Law Firm Files Securities Class Action Lawsuit Against Avalanche Biotechnologies, Inc.

The Rosen Law Firm, a global investor rights law firm, announces that it has filed a class action lawsuit on behalf of purchasers of Avalanche Biotechnologies, Inc.